epigenetics banner

Epitranscriptome Analysis

The epitranscriptome encompasses RNA modifications that influence RNA structure and function and regulate gene expression. More than a hundred and fifty distinct RNA modifications have been discovered in nature. Post-transcriptional regulatory markers occur in messenger RNAs (mRNAs), transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), circular RNAs (circRNAs), micro RNAs (miRNA), and long non-coding RNAs (lncRNAs). Liquid Chromatography Mass Spectrometry (LC-MS) is utilized to quantify the abundance of m5C, hm5C, f5C, ca5C, m4C, m6A, pseudouridine (Ψ), and many other modified RNA nucleotides. Next generation sequencing (NGS) can identify some of the modified RNA nucleotides in context of epitranscriptome-wide analyses. Epitranscriptomics is expanding with new profiling methods and discoveries of promising biomarkers and therapeutic targets.


RNA modifications with next generation sequencing or mass spectrometry for epitranscriptomics

RNA modifications with sequencing or LC-MS for epitranscriptomics


Profiling RNA modifications with sequencing or mass spectrometry

NEB offers enzymes, reagents, and kits that are ideal for NGS or LC-MS epitranscriptome analysis:

  • Our suite of Ribonucleases (RNases) have utilities for mapping RNA modifications with next generation sequencing or LC-MS.
  • RNase 4 (NEB #M1284) tolerates common RNA modifications and cleaves at uridine-purine (U/R) dinucleotide sites to generate a larger population of uniquely mappable oligonucleotides to improve RNA species characterization by LC-MS/MS.
  • Nucleoside Digestion Mix (NEB #M0649) digests RNA with common epitranscriptome modifications to single nucleosides in one step for quantitative analysis by LC-MS/MS.
  • XRN-1 (NEB # M0338) can be used to distinguish between capped and uncapped mRNA.
  • Sce Pseudouridine Synthase I (Sce PUS I) (NEB # M0526) isomerizes uridine to pseudouridine in predominantly single-stranded RNA in vitro.
  • EpiMark® N6-Methyladenosine Enrichment Kit (NEB #E1610) enriches m6A modified RNA in immunoprecipitation protocols for downstream next-generation sequencing or RT-qPCR.
  • Additionally, our NEBNext® next generation sequencing portfolio includes useful solutions for mapping the epitranscriptome.

 

Illumina® is a registered trademark of Illumina, Inc.


Choose Type:

FAQs for Epitranscriptome Analysis
Protocols for Epitranscriptome Analysis
Application Notes for Epitranscriptome Analysis
    Publications related to Epitranscriptome Analysis
    • Yan B. et al. (2021) ReCappable Seq: Comprehensive Determination of Transcription Start Sites derived from all RNA polymerases. Genome Research; DOI: 10.1101/gr.275784.121
    • Wolf, E.J., Grünberg, S., Dai, N., Chen, T.H., Roy, B., Yigit, E., Corrêa, I.R. (2022) Human RNase 4 improves mRNA sequence characterization by LC-MSMS. Nucleic Acids Res; Online ahead, PubMedID: 35871301, DOI: 10.1093/nar/gkac632
    • Wolf et al. (2023) Selective Characterization of mRNA 5′ End-Capping by DNA Probe-Directed Enrichment with Site-Specific Endoribonucleases. ACS Pharmacology & Translational Science; DOI: 10.1021/acsptsci.3c00157
    • Grünberg, S., Doyle, L. A., Wolf, E. J., Dai, N., Ivan R. Corrêa, J., Yigit, E., Stoddard, B. L. (2023) The structural basis of mRNA recognition and binding by eukaryotic pseudouridine synthase PUS1 bioRxiv; 2021.2012.2008.471817, PubMedID: 37939088, DOI: https://doi.org/10.1101/2021.12.08.471817
Legal Information

Products and content are covered by one or more patents, trademarks and/or copyrights owned or controlled by New England Biolabs, Inc (NEB). The use of trademark symbols does not necessarily indicate that the name is trademarked in the country where it is being read; it indicates where the content was originally developed. The use of this product may require the buyer to obtain additional third-party intellectual property rights for certain applications. For more information, please email busdev@neb.com.

This product is intended for research purposes only. This product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.